Siteone Therapeutics

Sodium ion channel 1.7 (Na 1.7) inhibitors for acute and chronic pain.

placeSan Francisco, California, United States calendar_todayFounded 2010 language siteonetherapeutics.com

Innovation

9 patent families (6 granted) — focus: Chemistry & metallurgy; filing pace slowing. Cited 1,254 times.

YearFilings
20151
20161
20172
20184
20192
20204
20213
20225
20234
20242
20254
20261

Investor mix

15 investors on record; lead investors include Sears Capital Management, Mission Bay Capital, Amgen, Novo Holdings; 2 have since exited.

Investor typeCountShare
Venture capital640%
Private equity213%
Angel & family office17%
Other / undisclosed640%
Coming soon